Tolvaptan Sandoz: Uses, Dosage & Side Effects
A selective vasopressin V2-receptor antagonist (aquaretic) used to treat hyponatremia in adults with the syndrome of inappropriate antidiuretic hormone secretion (SIADH)
Tolvaptan Sandoz is a generic prescription tablet containing the active substance tolvaptan, a selective, competitive antagonist of the arginine vasopressin V2 receptor. By blocking V2 receptors in the renal collecting duct, tolvaptan increases the excretion of free water without sodium loss — an effect called aquaresis. The 7.5 mg strength is typically used as a starting or titration dose in the treatment of clinically significant hypervolaemic and euvolaemic hyponatremia (low blood sodium) caused by the syndrome of inappropriate antidiuretic hormone secretion (SIADH). Tolvaptan is also used at higher doses in autosomal dominant polycystic kidney disease (ADPKD) to slow kidney cyst growth and the decline in kidney function. Treatment must always be started in a hospital so that serum sodium can be closely monitored, because an overly rapid rise in sodium can cause osmotic demyelination syndrome.
Quick Facts: Tolvaptan Sandoz
Key Takeaways
- Tolvaptan Sandoz is a generic tablet formulation of tolvaptan, a vasopressin V2-receptor antagonist that promotes loss of water in urine without loss of sodium or potassium (aquaresis).
- The 7.5 mg tablet is primarily used to correct clinically significant hyponatremia caused by SIADH in adults; higher total daily doses of tolvaptan (typically 60–120 mg in split dosing) are used to slow disease progression in autosomal dominant polycystic kidney disease (ADPKD).
- Treatment must be started in a hospital with frequent sodium monitoring during the first 24–48 hours because overly rapid sodium correction can cause osmotic demyelination syndrome (ODS), a serious neurological complication.
- Rare but serious idiosyncratic liver injury has been reported in ADPKD patients, which is why tolvaptan is dispensed through controlled access programmes with mandatory liver-function monitoring for this indication.
- Tolvaptan is a CYP3A4 substrate: strong CYP3A4 inhibitors (e.g. ketoconazole, itraconazole, clarithromycin, grapefruit juice) are contraindicated, and strong CYP3A4 inducers (e.g. rifampicin, St John's wort) should be avoided. Patients must have free access to water and be able to respond to thirst.
What Is Tolvaptan Sandoz and What Is It Used For?
Tolvaptan Sandoz is a generic medicinal product manufactured by Sandoz that contains the active pharmaceutical ingredient tolvaptan. Tolvaptan is the prototype member of a class of medicines called “vaptans” or selective vasopressin-receptor antagonists. More specifically, tolvaptan selectively blocks the V2 subtype of vasopressin receptors, which are located mainly on the cells that line the collecting duct of the nephron in the kidney. Because of its effect on water handling, tolvaptan is also described as an aquaretic — a medicine that promotes the loss of free water in urine while sparing electrolytes such as sodium and potassium.
Under normal physiological conditions, the hormone arginine vasopressin (AVP), also called antidiuretic hormone (ADH), is released from the posterior pituitary gland when the body senses rising plasma osmolality (concentration) or falling circulating blood volume. AVP binds to V2 receptors in the collecting duct, triggering an intracellular signalling cascade that inserts aquaporin-2 water channels into the apical cell membrane. Water then moves from the tubular fluid back into the body, producing concentrated urine and preserving blood volume. When V2 receptors are pharmacologically blocked by tolvaptan, aquaporin-2 channels are not inserted, so water passes through the collecting duct and is excreted. The result is dilute urine with a relatively preserved sodium content.
This mechanism has two clinically useful consequences that are exploited in two quite different indications:
- Treatment of hyponatremia in SIADH: In SIADH, inappropriate release of vasopressin causes the kidneys to retain too much water, diluting serum sodium. Tolvaptan directly counteracts this process, excreting the retained water and allowing serum sodium to rise toward normal.
- Slowing progression of ADPKD: In autosomal dominant polycystic kidney disease, abnormally high levels of cyclic AMP within cyst-lining cells drive cyst expansion. Because V2 receptor signalling is a major source of cyclic AMP in these cells, chronic V2 blockade with tolvaptan reduces cyst growth and slows the decline in kidney function.
Hyponatremia Secondary to SIADH
Hyponatremia (serum sodium < 135 mmol/L) is the most common electrolyte disturbance seen in hospitalised patients worldwide and is associated with increased morbidity, longer hospital stays and higher mortality. The most frequent cause of euvolaemic hyponatremia in adults is the syndrome of inappropriate antidiuretic hormone secretion (SIADH), in which vasopressin is released despite normal or low plasma osmolality. Common triggers include pulmonary disease (pneumonia, tuberculosis), central nervous system disorders (meningitis, stroke, subarachnoid haemorrhage), malignancies (especially small cell lung cancer) and a wide range of drugs (SSRIs, carbamazepine, vincristine, thiazides in some contexts).
First-line treatment of chronic euvolaemic hyponatremia typically includes fluid restriction, treatment of the underlying cause and, where appropriate, oral sodium supplementation or loop diuretics combined with salt. When these measures fail to produce a satisfactory rise in sodium, or when the patient is unable to tolerate fluid restriction, tolvaptan provides a targeted pharmacological option. The 7.5 mg strength is particularly useful for cautious up-titration, dose reduction in patients who respond too quickly, and long-term maintenance in those who need ongoing treatment at the lowest effective dose.
Patients with symptomatic hyponatremia may experience headache, nausea, vomiting, confusion, lethargy, falls, seizures or coma depending on how quickly the sodium has fallen and how low it is. Correcting sodium with tolvaptan is associated with improvement of cognitive performance, balance and quality of life in long-term cohort studies, but it must always be done slowly to avoid neurological complications.
Autosomal Dominant Polycystic Kidney Disease (ADPKD)
ADPKD is the most common inherited kidney disorder, affecting approximately 1 in 1,000 people. It is caused by mutations in the PKD1 or PKD2 genes that lead to progressive development of fluid-filled cysts in both kidneys. Over decades the cysts enlarge the kidneys, compress normal nephrons and eventually cause end-stage kidney disease (ESKD) in most affected individuals by the fifth to seventh decade of life. Tolvaptan was the first disease-modifying therapy shown in adequately powered trials to slow the rate of kidney volume increase and the decline in estimated glomerular filtration rate (eGFR) in adults with rapidly progressing ADPKD.
For this indication, tolvaptan is prescribed at much higher daily doses than in SIADH and under strict monitoring programmes due to the risk of idiosyncratic liver injury. The 7.5 mg tablet is generally not the strength used for ADPKD, but a patient may encounter 7.5 mg if specifically prescribed for dose titration or maintenance of hyponatremia separately. Always follow the indication and dose your prescriber has specified.
Although all tolvaptan products contain the same active substance, regulatory agencies and clinical practice distinguish clearly between use in hyponatremia (short courses, low doses, usually 7.5–60 mg once daily) and use in ADPKD (long-term treatment, higher daily doses split morning/afternoon, with mandatory liver-function monitoring and restricted distribution). The 7.5 mg strength of Tolvaptan Sandoz sits in the hyponatremia dose range.
How Tolvaptan Differs from Traditional Diuretics
Conventional diuretics such as furosemide (a loop diuretic) or hydrochlorothiazide (a thiazide diuretic) promote urine output mainly by blocking the reabsorption of sodium. Because water follows sodium, these drugs produce a “saluretic” diuresis that removes both sodium and water — sometimes worsening hyponatremia. Tolvaptan works further downstream at the V2 receptor and selectively removes water, so it can raise rather than lower serum sodium. This distinction is fundamental: tolvaptan is the first clinically practical aquaretic and should not be thought of as a diuretic in the classic sense.
Because sodium is preserved, patients taking tolvaptan need to pay careful attention to their fluid intake and thirst. Dehydration can develop quickly if water is not replaced, particularly in elderly patients and in those who have impaired thirst perception.
What Should You Know Before Taking Tolvaptan Sandoz?
Contraindications
There are several situations in which Tolvaptan Sandoz must not be used. These absolute contraindications apply whether the drug is prescribed for hyponatremia or for ADPKD.
- Hypersensitivity: Known allergy to tolvaptan, to benzazepines (a chemical class that includes tolvaptan) or to any of the excipients of the tablet.
- Anuria: Patients who produce no urine cannot benefit from a drug that acts on the collecting duct and should not receive tolvaptan.
- Volume depletion: Patients with significant hypovolaemia (low circulating blood volume) in whom further water loss would be dangerous.
- Hypovolaemic hyponatremia: Tolvaptan is not licensed for hyponatremia associated with volume depletion (e.g. diarrhoea, vomiting or diuretic overuse); such patients need sodium and fluid replacement, not aquaresis.
- Hypernatremia: Elevated serum sodium (> 145 mmol/L) at baseline.
- Inability to sense or respond appropriately to thirst: Because tolvaptan causes loss of water through the urine, patients must be able to drink freely in response to thirst. Those with impaired consciousness, advanced dementia, hypothalamic disorders of thirst or restricted oral access to fluids are at high risk of rapid, dangerous dehydration and hypernatremia.
- Pregnancy and breastfeeding: Tolvaptan should not be used during pregnancy or breastfeeding because of reproductive toxicity seen in animals and possible excretion into milk.
- Severe liver disease (for the ADPKD indication): Significant baseline liver impairment, elevated liver enzymes or a history of drug-induced liver injury contraindicates long-term high-dose tolvaptan for ADPKD.
Warnings and Precautions
Too rapid correction of chronic hyponatremia (> 10–12 mmol/L rise in 24 hours or > 18 mmol/L in 48 hours) can cause osmotic demyelination syndrome, a potentially fatal and often irreversible neurological complication causing dysarthria, dysphagia, paraparesis/quadriparesis, confusion, seizures and coma. To reduce this risk, Tolvaptan Sandoz must be started in a hospital, with frequent sodium measurements during the first 24–48 hours. Fluid restriction is usually avoided during the first 24 hours of therapy. If sodium rises too quickly, the dose is reduced or interrupted, and free water (e.g. oral water, 5% dextrose or desmopressin) may be administered to slow the rise.
In clinical trials of tolvaptan for ADPKD, a small number of patients developed marked elevations of ALT or AST with rising bilirubin. Some cases met the criteria for drug-induced liver failure (DILI). Liver function tests must be measured before starting tolvaptan for ADPKD, monthly during the first 18 months, and at least every 3 months thereafter. Patients must report symptoms such as fatigue, anorexia, nausea, right upper quadrant discomfort, dark urine, pruritus or jaundice immediately. Treatment must be discontinued permanently if ALT or AST is > 8 times the upper limit of normal, or if ALT/AST > 3× ULN is accompanied by total bilirubin > 2× ULN.
Before starting Tolvaptan Sandoz, tell your doctor if any of the following apply to you:
- Kidney disease: Patients with advanced chronic kidney disease may respond less predictably. For the ADPKD indication, tolvaptan is usually not effective below an eGFR of approximately 25–30 mL/min/1.73 m2.
- Liver disease: Mild-to-moderate hepatic impairment increases exposure to tolvaptan. Pre-existing liver disease or elevated liver enzymes require caution. The product is contraindicated in severe hepatic impairment and for long-term ADPKD use if baseline liver tests are abnormal.
- Diabetes mellitus: Marked hyperglycaemia may cause pseudohyponatremia that does not benefit from tolvaptan. Blood sugar should be corrected first. Dehydration during treatment can worsen diabetic control.
- Heart failure: Tolvaptan has been studied in heart failure with hyponatremia; it improves symptoms temporarily but was not shown to reduce long-term mortality in the EVEREST trials. Your cardiologist will decide whether it is appropriate and will monitor fluid balance.
- Urinary outflow obstruction: The increased urine volume can precipitate urinary retention in patients with prostatic or other obstructive uropathy.
- Electrolyte disturbances: Low potassium or magnesium should be corrected before and during treatment.
- Elderly patients: Older adults are more prone to dehydration, rapid sodium rise and falls related to polyuria and may need lower starting doses and closer monitoring.
- Anaphylaxis and other hypersensitivity reactions: Rare cases of anaphylaxis, rash, angioedema and pruritus have been reported. Seek immediate medical care for facial swelling, difficulty breathing or widespread urticaria.
- Hyperuricaemia and gout: Tolvaptan raises serum uric acid levels and has occasionally precipitated gout flares. Monitor uric acid if you have a history of gout.
Pregnancy and Breastfeeding
Tolvaptan has shown reproductive toxicity in animal studies, including reduced fetal weight and skeletal anomalies at doses producing clinically relevant exposures. Clinical data in pregnant women are limited. Tolvaptan Sandoz is not recommended during pregnancy, and women of childbearing potential must use effective contraception during treatment. If you become pregnant while on tolvaptan, inform your doctor immediately so that treatment can be reviewed.
It is not known whether tolvaptan is excreted in human breast milk. In lactating rats, tolvaptan and its metabolites were detected in milk, suggesting the possibility of excretion in humans. Because of the risk of water loss in a nursing infant, breastfeeding is contraindicated during treatment with Tolvaptan Sandoz.
Fertility studies in animals did not show meaningful adverse effects on fertility, but data in humans are lacking.
Driving and Operating Machinery
Tolvaptan is not expected to have a clinically important effect on driving or using machinery. However, if you experience dizziness, lightheadedness due to dehydration or low blood pressure, or disorientation from rapid changes in sodium, do not drive or use machinery until these symptoms resolve. Patients recovering from hyponatremia-related neurological symptoms should defer driving until judged fit by their doctor.
Important Information About Excipients
Tolvaptan Sandoz tablets contain lactose monohydrate as a filler. If you have been told by your doctor that you have an intolerance to certain sugars (such as galactose intolerance, total lactase deficiency or glucose-galactose malabsorption), you should discuss this with your doctor before taking Tolvaptan Sandoz. The tablets contain less than 1 mmol sodium (23 mg) per tablet, meaning they are essentially “sodium-free”.
How Does Tolvaptan Sandoz Interact with Other Drugs?
Tolvaptan is almost exclusively metabolised by the hepatic cytochrome P450 3A4 (CYP3A4) enzyme, and to a lesser extent CYP3A5. It is also a substrate and weak inhibitor of the efflux transporter P-glycoprotein (P-gp) and of the hepatic uptake transporters OATP1B1 and OATP1B3. These pharmacokinetic characteristics mean that tolvaptan has a relatively large number of clinically meaningful drug–drug interactions. In addition, pharmacodynamic interactions arise whenever tolvaptan is co-administered with medicines that affect serum sodium, fluid balance or the renin-angiotensin system.
Major Interactions
| Interacting Drug or Class | Effect | Clinical Significance |
|---|---|---|
| Strong CYP3A4 inhibitors (ketoconazole, itraconazole, clarithromycin, telithromycin, ritonavir, cobicistat, nefazodone) | 5- to 10-fold increase in tolvaptan plasma levels; risk of excessive aquaresis, dehydration and dangerous sodium rise | Contraindicated — do not combine |
| Grapefruit and grapefruit juice | Inhibits intestinal CYP3A4, raising tolvaptan exposure 1.8- to 2-fold | Avoid while on treatment |
| Strong CYP3A4 inducers (rifampicin, rifabutin, rifapentine, phenytoin, carbamazepine, phenobarbital, St John's wort) | Up to 85% reduction in tolvaptan exposure; loss of efficacy | Avoid; dose increase unlikely to overcome induction safely |
| Hypertonic saline (3% NaCl) and other vaptans (e.g. conivaptan) | Additive rise in serum sodium; risk of osmotic demyelination | Do not combine routinely; close ICU monitoring if ever required |
| High-dose loop or thiazide diuretics during tolvaptan initiation | Risk of volume depletion, rapid sodium rise and acute kidney injury | Use cautiously; frequent monitoring of sodium, weight and renal function |
| Potassium supplements / potassium-sparing diuretics (spironolactone, eplerenone, amiloride) | Potential hyperkalaemia, especially when kidney function is reduced | Monitor potassium closely; adjust doses as needed |
Moderate and Minor Interactions
| Interacting Drug or Class | Effect | Clinical Significance |
|---|---|---|
| Moderate CYP3A4 inhibitors (fluconazole, erythromycin, verapamil, diltiazem) | Approximate doubling of tolvaptan AUC | Consider dose reduction (e.g. halving the daily dose) and monitor sodium frequently |
| Moderate CYP3A4 inducers (efavirenz, modafinil) | Moderate reduction in tolvaptan exposure | Monitor clinical response; dose adjustment may be needed |
| Digoxin | Tolvaptan inhibits P-gp, raising digoxin levels approximately 1.3-fold | Monitor digoxin levels and signs of toxicity; dose adjustment may be needed |
| Warfarin and other vitamin K antagonists | No direct pharmacokinetic interaction, but aquaresis and fluctuating fluid status may alter INR | Monitor INR more frequently during initiation and dose changes |
| ACE inhibitors, ARBs, renin inhibitors | Additive effects on blood pressure and serum potassium | Monitor blood pressure and potassium, especially in elderly or CKD patients |
| Desmopressin (DDAVP) | Pharmacological antagonism at V2 receptor, reducing antidiuretic effect | Avoid routine concurrent use; however, desmopressin may be used deliberately to slow an overly rapid sodium correction under specialist supervision |
| OATP1B1/1B3 substrates (statins such as rosuvastatin) | Possible modest increase in substrate levels | Monitor for adverse effects; dose adjustment rarely required |
Because of the clinical importance of these interactions, a full medication review — including over-the-counter products, herbal medicines and recreational substances — should be performed before starting Tolvaptan Sandoz. Pharmacists play a key role in identifying and managing CYP3A4 interactions and should be informed whenever another prescriber introduces a new medicine.
Tolvaptan can be taken with or without food, but grapefruit and grapefruit juice should be avoided as they inhibit CYP3A4. Limit alcohol because it may worsen dehydration. Ensure generous free-water intake (generally at least 2 litres per day unless contraindicated) and keep water available overnight to quench thirst safely.
What Is the Correct Dosage of Tolvaptan Sandoz?
Tolvaptan Sandoz is taken by mouth as a whole tablet, with water, at approximately the same time each day. The dose schedule depends on the indication, the patient's response and the treating specialist's judgement. Treatment for hyponatremia should always be initiated in a hospital setting with appropriate facilities to monitor serum sodium and neurological status, at least for the first 24–48 hours. Fluid restriction should typically be avoided during the first 24 hours of therapy.
Adults — Hyponatremia (SIADH)
Standard Initial Regimen
Starting dose: 15 mg once daily.
Titration: The dose may be increased to 30 mg once daily after at least 24 hours, and up to a maximum of 60 mg once daily, to achieve the desired serum sodium level.
Target rate: Do not exceed a rise of 10–12 mmol/L in the first 24 hours and 18 mmol/L in 48 hours. For high-risk patients (e.g. chronic hyponatremia, malnutrition, hypokalaemia, advanced liver disease) a more cautious target of 8 mmol/L in 24 hours may be preferred.
Role of the 7.5 mg Tablet
The 7.5 mg strength allows fine-tuned dose adjustment in patients who are sensitive to tolvaptan, elderly patients, those with impaired hepatic function, or those on interacting medications such as moderate CYP3A4 inhibitors. A common strategy is:
- Start or down-titrate to 7.5 mg once daily when a slower correction is required.
- Use 7.5 mg as the maintenance dose in patients whose sodium is adequately controlled on the lowest effective amount.
- Step down from 15 mg to 7.5 mg if polyuria, thirst or laboratory trends suggest that lower exposure is preferable.
Adults — Autosomal Dominant Polycystic Kidney Disease (ADPKD)
For the ADPKD indication, tolvaptan is given in a split, morning-heavy regimen with higher total daily doses. Although most ADPKD patients receive their dose from a 15/30/45/60/90 mg tablet combination, the 7.5 mg strength is occasionally relevant during gradual up-titration or dose reduction in patients experiencing aquaresis-related symptoms. Only prescribers registered with the applicable controlled-access programme may initiate or continue treatment for ADPKD.
Standard ADPKD Titration Schedule
- Week 1–3: 45 mg on waking + 15 mg approximately 8 hours later (total 60 mg/day)
- Next step: 60 mg + 30 mg (total 90 mg/day)
- Target dose (if tolerated): 90 mg + 30 mg (total 120 mg/day)
Doses are taken with plenty of water. Mandatory monthly liver-function tests during the first 18 months are part of the access programme.
Children and Adolescents
The safety and efficacy of Tolvaptan Sandoz have not been established in children and adolescents under 18 years of age for either hyponatremia or ADPKD. Therefore, Tolvaptan Sandoz is not recommended for use in this population outside of carefully designed clinical trials under specialist supervision.
Elderly Patients
No specific dose adjustment is required based on age alone. However, because of the higher prevalence of impaired thirst perception, reduced mobility (making it harder to reach water or toilet during polyuria), polypharmacy (more CYP3A4 interactions), and greater susceptibility to falls and dehydration, the lowest effective dose should be used in older adults, preferably starting at 7.5 mg and titrating slowly. Frequent clinical review and laboratory monitoring are particularly important.
Renal and Hepatic Impairment
- Renal impairment: No dose adjustment is needed based on estimated glomerular filtration rate alone for the hyponatremia indication. Tolvaptan is not expected to be effective in anuric patients. For ADPKD, efficacy diminishes in advanced CKD and treatment is generally stopped if eGFR falls below around 25–30 mL/min/1.73 m2.
- Mild-to-moderate hepatic impairment: Use with caution; consider a lower starting dose (e.g. 7.5 mg) and closer laboratory monitoring, since tolvaptan exposure may be increased.
- Severe hepatic impairment or liver failure: Tolvaptan is contraindicated.
Missed Dose
If you forget a dose, take it as soon as you remember that same day, unless it is almost time for your next dose. In that case, skip the missed dose and continue with your usual schedule. Do not take a double dose to make up for a missed one. If you miss doses repeatedly, tell your doctor or pharmacist, because irregular dosing can destabilise your sodium level. Use a pill organiser, a phone alarm or a medication app to improve adherence if needed.
Overdose
Acute overdose of tolvaptan would be expected to produce excessive aquaresis — severe thirst, polyuria, hypernatremia, dehydration, hypotension and, potentially, rapid rise in serum sodium that could precipitate osmotic demyelination. There is no specific antidote. Management is supportive: stop further tolvaptan, allow free oral intake of water if the patient can swallow safely, and administer intravenous hypotonic fluids (e.g. 0.45% saline or 5% glucose) under laboratory guidance. Desmopressin may be used cautiously under specialist advice if over-correction of sodium has occurred. Haemodialysis is not effective because tolvaptan is extensively protein-bound. Seek urgent medical care if overdose is suspected.
During the early phase of Tolvaptan Sandoz therapy, expect your medical team to check: serum sodium every 6–8 hours in the first 24–48 hours and daily for several days thereafter; body weight and fluid intake/output; blood pressure and pulse; potassium, urea, creatinine and liver enzymes (ALT, AST, bilirubin); signs of dehydration or neurological change. You should drink water freely in response to thirst unless specifically told otherwise.
What Are the Side Effects of Tolvaptan Sandoz?
Like all medicines, Tolvaptan Sandoz can cause side effects, although not everybody will experience them. Many of the most common adverse effects relate directly to aquaresis — the intended pharmacological action — and are usually manageable with adequate water intake and dose adjustment. Other effects are idiosyncratic or dose-related and may require stopping therapy. Side-effect frequencies below are compiled from pooled SIADH and ADPKD clinical trial data; the spectrum at long-term high doses for ADPKD is broader than at short-term low doses for hyponatremia.
Side Effects by Frequency
Very Common
May affect more than 1 in 10 people
- Thirst
- Dry mouth
- Polyuria (increased urine output)
- Pollakiuria (frequent urination)
- Nocturia (night-time urination)
- Nausea
- Headache
- Dizziness
- Fatigue (tiredness)
- Decreased appetite (in ADPKD long-term)
- Hyperuricaemia (raised blood uric acid)
Common
May affect up to 1 in 10 people
- Dehydration
- Hypernatremia (high blood sodium)
- Hypokalaemia (low blood potassium)
- Hyperglycaemia (raised blood sugar)
- Orthostatic hypotension (dizziness on standing)
- Palpitations
- Diarrhoea or constipation
- Abdominal pain
- Dyspepsia (indigestion)
- Rash and pruritus (itching)
- Elevated ALT/AST (liver enzymes)
- Gout (especially in ADPKD cohorts)
- Pyrexia (fever)
- Weight loss from fluid shift
- Muscle spasms
Uncommon
May affect up to 1 in 100 people
- Hypotension (low blood pressure)
- Fainting (syncope)
- Acute kidney injury due to severe volume depletion
- Marked elevation of ALT, AST and/or bilirubin
- Disseminated intravascular coagulation (reported rarely in clinical trials)
- Ischaemic colitis
- Ventricular fibrillation (reported rarely in trials)
- Urticaria (hives)
- Angioedema
Rare
May affect up to 1 in 1,000 people
- Anaphylaxis
- Severe idiosyncratic hepatotoxicity that may rarely progress to liver failure (ADPKD indication)
- Osmotic demyelination syndrome from overly rapid sodium correction
- Stevens-Johnson syndrome and toxic epidermal necrolysis (post-marketing reports)
- Severe urinary retention in predisposed patients
Not Known
Frequency cannot be estimated from available data
- Hepatitis and cholestatic liver injury beyond trial-derived frequencies
- Hypersensitivity with generalised rash, eosinophilia and systemic symptoms (DRESS)
- Rhabdomyolysis in rare post-marketing reports
- Severe dehydration leading to thromboembolic events
Managing Common Side Effects
Thirst, dry mouth and increased urination are the signature effects of V2-receptor blockade and are experienced by almost all patients to some degree. The following measures help patients adapt:
- Drink to thirst: Keep water readily available at all times, including at the bedside overnight. Most patients need 2–4 litres per day. Do not deliberately restrict fluids unless your doctor specifically asks you to.
- Plan urination: Because of marked polyuria, plan access to a toilet for several hours after each dose. Many patients prefer to take the morning dose early so that most of the aquaresis occurs during waking hours.
- Check your weight: Daily weights can help detect both over-correction (excessive weight loss) and under-response (persistent fluid overload in heart failure or liver disease).
- Watch for warning signs: Call your healthcare provider urgently if you develop confusion, severe headache, slurred speech, weakness, high fever, jaundice, severe rash, facial swelling, breathing difficulty, chest pain or inability to drink.
Older adults experience more dehydration, orthostatic hypotension, falls and hypernatremia than younger patients. Ensure your care team knows your age, baseline cognition, access to fluids (particularly at night), and any urinary symptoms before starting treatment. Lower starting doses such as 7.5 mg once daily are often preferred in frail older patients.
If you experience any side effects, including those not listed here, tell your doctor, nurse or pharmacist. You can also report suspected side effects to your national pharmacovigilance authority (e.g. EudraVigilance in Europe, FDA MedWatch in the United States, MHRA Yellow Card Scheme in the United Kingdom) to help monitor the ongoing benefit-risk profile of Tolvaptan Sandoz.
How Should Tolvaptan Sandoz Be Stored?
Correct storage ensures that every tablet you take contains exactly the labelled amount of tolvaptan. Specific instructions for Tolvaptan Sandoz are:
- Temperature: Store below 25°C (77°F). Do not freeze.
- Moisture: Keep the tablets in the original blister packaging until you take them. Do not decant into pill boxes for long periods unless specifically advised, as humidity can degrade tolvaptan.
- Light: Keep the blister in the outer carton to protect from light.
- Location: Store in a dry place, such as a bedroom drawer or medicine cabinet, away from the bathroom where humidity can be high.
- Children and pets: Keep out of the sight and reach of children and pets. Accidental ingestion can cause dangerous aquaresis in small bodies.
- Expiry date: Do not use Tolvaptan Sandoz after the expiry (EXP) date printed on the carton and blister. The expiry date refers to the last day of that month.
- Disposal: Do not throw away unused tablets via wastewater or household waste. Return them to your community pharmacy for incineration as clinical waste. These measures will help protect the environment.
If you are travelling across time zones, plan ahead to maintain consistent dosing intervals and always keep tolvaptan in your hand luggage together with a copy of your prescription and a letter from your doctor. Ensure you have access to safe drinking water throughout your journey.
What Does Tolvaptan Sandoz Contain?
Active Substance
The active substance is tolvaptan. Each film-coated tablet contains 7.5 mg of tolvaptan (INN, international non-proprietary name). Tolvaptan is a non-peptide benzazepine derivative with selective antagonist activity at the V2 vasopressin receptor and minimal affinity for V1a, V1b and oxytocin receptors. Its chemical name is (±)-4'-[(7-chloro-5-hydroxy-2,3,4,5-tetrahydro-1H-1-benzazepin-1-yl)carbonyl]-o-tolu-m-toluidide, molecular formula C26H25ClN2O3, molecular weight 448.9 g/mol.
Inactive Ingredients (Excipients)
Generic tolvaptan tablets typically contain:
- Lactose monohydrate (filler)
- Maize (corn) starch
- Microcrystalline cellulose
- Hydroxypropylcellulose (low-substituted)
- Magnesium stearate (lubricant)
- Indigo carmine aluminium lake (colourant, may vary by strength)
- Film coat: hypromellose, titanium dioxide, talc and other pharmacopoeial film-forming agents
The precise excipient list for the batch you receive is printed in the patient information leaflet supplied with the medication. If you have a known allergy to any excipient, verify the leaflet before taking the tablet.
Appearance
Tolvaptan Sandoz 7.5 mg is supplied as an oral film-coated tablet in a blister pack with an outer carton containing the patient leaflet. Pack sizes vary by country and market, commonly from single blister strips for short hospital courses to multi-strip packs for longer-term maintenance. The specific colour, shape and debossing of the tablet depend on the national authorisation and are illustrated in the leaflet.
Marketing Authorisation Holder and Manufacturer
Tolvaptan Sandoz is marketed by Sandoz, a division of Novartis specialising in generic medicines. The marketing authorisation holder of record and the manufacturing sites are specified in the patient leaflet and on the outer carton. If you need country-specific information, contact your local Sandoz affiliate or your dispensing pharmacy.
Frequently Asked Questions About Tolvaptan Sandoz
Tolvaptan Sandoz is a generic tablet containing tolvaptan, a selective vasopressin V2-receptor antagonist. In the 7.5 mg strength it is primarily used to treat hyponatremia (low blood sodium) caused by the syndrome of inappropriate antidiuretic hormone secretion (SIADH) in adults. Higher-strength tolvaptan products are also licensed to slow disease progression in autosomal dominant polycystic kidney disease (ADPKD). Always follow your doctor's specific indication and dose.
The aquaretic effect begins within 2–4 hours of a single oral dose, with a measurable fall in urine osmolality and a rise in urine output. Serum sodium typically begins to rise within 4–8 hours and reaches its peak change in the first 24–48 hours. That is exactly why hospital monitoring is essential during the first two days — the drug is fast-acting and too much can be dangerous. Steady-state after repeated dosing is reached in 3–5 days.
There is no specific pharmacokinetic interaction between moderate alcohol use and tolvaptan, but alcohol can contribute to dehydration and orthostatic hypotension, and in heavy drinkers it can also affect liver function. Because tolvaptan already causes pronounced diuresis and is occasionally associated with liver enzyme elevations, most specialists advise limiting alcohol intake during treatment. Avoid binge drinking and ensure extra water intake on social occasions.
Rapid correction of chronic hyponatremia can cause osmotic demyelination syndrome, in which the brain's myelin sheaths are damaged as cells adapt too quickly to the new osmotic environment. This complication can cause permanent neurological disability or death. Blood tests every 6–8 hours during the first day, and daily thereafter, allow your team to adjust or hold the tolvaptan dose before sodium rises beyond 10–12 mmol/L in 24 hours or 18 mmol/L in 48 hours.
Tolvaptan Sandoz is a generic version of the originator product. The active substance (tolvaptan), dose strength (7.5 mg), oral route and therapeutic indications overlap with the reference product Samsca (hyponatremia) marketed by Otsuka. Generic equivalence means the drug delivers the same amount of tolvaptan to the bloodstream within accepted statistical limits. Samsca is typically used for hyponatremia in SIADH, while Jinarc (EMA) and Jynarque (FDA) are brands of tolvaptan specifically licensed for ADPKD. Tolvaptan Sandoz 7.5 mg sits in the hyponatremia dose range and should only be used for the indication specified by your prescriber.
Tolvaptan itself is not directly nephrotoxic. However, severe dehydration from excessive aquaresis, or from being unable to respond to thirst, can cause acute kidney injury. In most reported cases, kidney function has recovered after rehydration and dose adjustment. Patients should drink water freely in response to thirst, keep water available overnight and report symptoms such as lightheadedness, very dark urine, very low urine output, confusion or worsening kidney function promptly.
If you vomit within 30 minutes of taking Tolvaptan Sandoz and you can see the intact tablet, you may not have absorbed a meaningful amount; discuss with your pharmacist or clinician whether to repeat the dose. If you vomit after more than 30 minutes, absorption is likely to have occurred and you should not take an additional tablet; continue with your next scheduled dose. Persistent vomiting can lead to dehydration and should be evaluated medically.
References
- European Medicines Agency (EMA). Samsca (tolvaptan) — Summary of Product Characteristics. Last updated 2025. Available from: EMA EPAR — Samsca.
- European Medicines Agency (EMA). Jinarc (tolvaptan) — Summary of Product Characteristics. Last updated 2025. Available from: EMA EPAR — Jinarc.
- U.S. Food and Drug Administration (FDA). Samsca (tolvaptan) Prescribing Information. Revised 2024. Available from: FDA Drug Label — Samsca.
- U.S. Food and Drug Administration (FDA). Jynarque (tolvaptan) Prescribing Information. Revised 2024. Available from: FDA Drug Label — Jynarque.
- Schrier RW, Gross P, Gheorghiade M, et al. Tolvaptan, a Selective Oral Vasopressin V2-Receptor Antagonist, for Hyponatremia (SALT-1 and SALT-2). N Engl J Med. 2006;355(20):2099–2112. doi:10.1056/NEJMoa065181.
- Torres VE, Chapman AB, Devuyst O, et al. Tolvaptan in Patients with Autosomal Dominant Polycystic Kidney Disease (TEMPO 3:4). N Engl J Med. 2012;367(25):2407–2418. doi:10.1056/NEJMoa1205511.
- Torres VE, Chapman AB, Devuyst O, et al. Tolvaptan in Later-Stage Autosomal Dominant Polycystic Kidney Disease (REPRISE). N Engl J Med. 2017;377(20):1930–1942. doi:10.1056/NEJMoa1710030.
- Spasovski G, Vanholder R, Allolio B, et al. Clinical practice guideline on diagnosis and treatment of hyponatraemia. Eur J Endocrinol. 2014;170(3):G1–G47. doi:10.1530/EJE-13-1020.
- Chebib FT, Perrone RD, Chapman AB, et al. A Practical Guide for Treatment of Rapidly Progressive ADPKD with Tolvaptan. J Am Soc Nephrol. 2018;29(10):2458–2470. doi:10.1681/ASN.2018060590.
- Verbalis JG, Goldsmith SR, Greenberg A, et al. Diagnosis, evaluation, and treatment of hyponatremia: expert panel recommendations. Am J Med. 2013;126(10 Suppl 1):S1–S42. doi:10.1016/j.amjmed.2013.07.006.
- Kidney Disease: Improving Global Outcomes (KDIGO). Controversies Conference on Autosomal Dominant Polycystic Kidney Disease — Executive Summary. Kidney Int. 2023;103(6):1024–1039.
- World Health Organization (WHO). WHO Model List of Essential Medicines — 23rd List. Geneva: WHO; 2023.
- Watkins PB, Lewis JH, Kaplowitz N, et al. Clinical Pattern of Tolvaptan-Associated Liver Injury in Subjects with Autosomal Dominant Polycystic Kidney Disease: Analysis of the Pivotal Clinical Trials. Drug Saf. 2015;38(11):1103–1113. doi:10.1007/s40264-015-0327-3.
Editorial Team
This article was written and reviewed by the iMedic Medical Editorial Team, comprising licensed specialist physicians with expertise in nephrology, endocrinology and clinical pharmacology.
Medical Content
iMedic Nephrology & Endocrinology Editorial Team — specialist physicians with clinical experience in SIADH, hyponatremia management and ADPKD
Medical Review
iMedic Medical Review Board — independent panel verifying accuracy against EMA SmPC, FDA label, ERA-EDTA, KDIGO and international consensus guidelines
Pharmacology Review
iMedic Clinical Pharmacology Team — specialists in drug interactions, pharmacokinetics and medication safety, with particular expertise in CYP3A4 interactions
Accessibility & SEO
iMedic Digital Health Team — ensuring WCAG 2.2 AAA compliance and optimal search visibility for patients and caregivers
All content follows the GRADE evidence framework and is reviewed according to international medical guidelines. iMedic receives no commercial funding from pharmaceutical companies.